<DOC>
	<DOCNO>NCT02947893</DOCNO>
	<brief_summary>The investigator hypothesize Nilotinib safe individual mild moderate AD . Specifically , investigator hypothesize low daily oral dos Nilotinib lead CSF penetration , CNS Abl inhibition , stabilization CSF total Tau p-Tau231/181 Abeta42/40 level . The investigator hypothesize Nilotinib decrease brain load amyloid use amyloid positron emission tomography ( PET ) . The investigator also predict Nilotinib reduce CSF marker cell death , include neuron specific enolase ( NSE ) S100B .</brief_summary>
	<brief_title>Impact Nilotinib Safety , Biomarkers Clinical Outcomes Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description>The investigator propose novel treatment strategy involve Abl inhibition alter Abeta40/42 , total Tau p-Tau231/181 subject mild moderate dementia due AD . The investigator pre-clinical study show Nilotinib inhibits brain Abl , decrease Abeta p-Tau , modulate brain peripheral immune profile reverse cognitive decline AD model . Taken together , data support hypothesis Nilotinib viable therapeutic candidate - via Abl inhibition - subject AD . Based strong pre-clinical evidence effect Nilotinib neurodegenerative pathology , include autophagic clearance neurotoxic protein , immunity behavior , investigator conduct open label pilot clinical trial advance ( stage 3-5 ) PD dementia ( PDD ) Lewy Body Dementia ( LBD ) patient . Participants ( N=12 ) randomize 1:1 daily oral dose 150mg 300mg Nilotinib 6 month . The investigator show Nilotinib penetrates blood brain barrier ( BBB ) , agreement pre-clinical data . Several study show Abeta42 decrease CSF total Tau p-Tau increase PD LBD . Investigators data show Nilotinib reverse loss CSF Abeta40/42 significantly reduce ( N=5 , P &lt; 0.05 ) CSF total Tau p-Tau baseline 6 month treatment . These biomarker change consistent cognitive improvement ( 3.5-3.85 point ) use Mini-Mental Status Exam ( MMSE ) Scales Outcomes Parkinson 's Disease-Cognition ( SCOPA-Cog ) baseline 6 month . These data compel evaluate effect Nilotinib phase II , randomize , double-blind , placebo-controlled trial patient mild moderate AD .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>1 . Age ≥ 50 2 . Fluent English 3 . Biomarker confirm AD CSF level Abeta42 &lt; 600ng/mL 4 . Able ingest oral medication 5 . Diagnosis mild moderate AD accord dementia criterion outline McKhann et al . 6 . Neuroimaging ( MRI CT ) consistent diagnosis AD within past year 7 . MMSE 17 24 ( inclusive ) screen 8 . Modified Hachinski score ≤ 4 9 . QTc interval 350460ms , inclusive 10 . Caregiver/study partner accompany participant visit direct contact participant &gt; 2 days/week 11 . Written inform consent 12 . Capability willingness comply study criteria 13 . Supervision available study medication 14 . Stable medical condition 3 month prior screen visit 15 . Stable medication 4 week prior screen visit 16 . Able complete baseline assessment 17 . Minimum 6 year education , work history sufficient exclude mental retardation 18 . Stable use cholinesterase inhibitor memantine ( U.S. FDAapproved medication patient probable AD ) , vitamin E ( 400 IU daily ) , estrogens , aspirin ( 81300 mg daily ) , cholesterollowering agent 3 month prior screen allow . 19 . Clinical laboratory value within normal limit , abnormal , must judge clinically insignificant investigator 1 . NonAD dementia , probable AD Down syndrome , APP , PS1 , PS2 mutation ( know familial AD ) , LBD Frontotemporal dementia ( FTD ) 2 . History clinically significant stroke 3 . Current evidence history past two year epilepsy , focal brain lesion , head injury loss consciousness DSMIV criterion major psychiatric disorder include psychosis , major depression , bipolar disorder , alcohol substance abuse 4 . Sensory impairment would preclude participation/cooperation protocol 5 . Patients hypokalemia , hypomagnesaemia , long QTc syndrome . 6 . Concomitant drug know prolong QTc interval ( &gt; 461ms ) history cardiovascular disease , include myocardial infarction cardiac failure , angina , arrhythmia 7 . Prescribed strong CYP3A4 inhibitor medical history liver pancreatic disease 8 . Evidence significant clinical disorder laboratory find render participant unsuitable receive investigational drug include clinically significant unstable hematologic , hepatic , cardiovascular , pulmonary , gastrointestinal , endocrine , metabolic , renal systemic disease laboratory abnormality 9 . Active neoplastic disease , history cancer five year prior screen , include breast cancer ( history treat basal squamous skin cancer , stable prostate cancer exclusionary ) 10 . Pregnancy possible pregnancy 11 . Contraindications LP : prior lumbosacral spine surgery , severe degenerative joint disease deformity spine , platelet &lt; 100,000 , use Coumadin/warfarin , history bleed disorder 12 . Contraindication MRI 13 . Evidence 4 micro hemorrhage and/or hemosiderosis recent ( 12 month ) and/or screen MRI . 14 . A low B12 exclusionary , unless followup lab ( homocysteine ( HC ) methylmalonic acid ( MMA ) ) indicate physiologically significant . 15 . Enrolled another active trial investigate experimental drug therapy AD 16 . HIV positive</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Nilotinib Alzheimer 's disease</keyword>
</DOC>